Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 14/February/2019, 6.41 am

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 14/February/2019, 6.29 am
February 14, 2019
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA DANCR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 14/February/2019, 6.48 am
February 14, 2019
Show all

Introduction: What they say:  

A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity against microbial infection.” This study was published, in the 2 March 2015 issue of the Journal “Nature Immunology” [the number one journal in immunological research with an impact factor of  24.973], by Drs. Zusen Fan, Xia and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene


From Research Findings to Therapeutic Opportunity:

This study suggests, for the first time, the dyslipidemia drug Ezetimibeby decreasing the expression of its target gene, it may : (1) increase the expression of Sox2; (2) increase the ability of Sox2 to recognize bacterial DNA in the cytoplasm; and (3) promote innate immunity against bacterial infection. 

Figure 1. Immune enhancement therapy. Ezetimibe, by increasing the expression of its target genes, it increases the expression of Sox-2 and its downstream components in the signaling pathway. And, thereby, promotes anti-bacterial immunity.

Figure 2. Ezetimibe may increase resistance against bacterial infection through induction of Sox2

Together, pharmacological formulations encompassing “Ezetimibe or its analogs,  either alone or in combination with other drugs, may be used to (1) enhance innate immunity against bacterial infection; and (2) promote bacterial resistance (figs. 1-2). 


Details of the research findings

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does ezetimibe enhance innate immunity against bacterial infection?

Amount: $750

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

CitationBoominathan, L., Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 14/February/2019, 6.41 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.